The disclosure comes as another of Arcus's TIGIT trials flops.
ApexOnco Front Page
Recent articles
Lilly makes its second in vivo Car-T acquisition, buying the privately held Kelonia for $3.25bn.
The groups spend big on Terns and Arcellx.
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
Rinzimetostat efficacy wanes further as the company moves into phase 3.
Replimune gets a second chance, while Sarclisa could go subcutaneous.
The group wants to improve on its own Welireg in a new phase 3 trial.
After a delay, the Alpha-3 study faces an April futility analysis.
